We, Xi’an Wanlong Pharmaceutical Co., Ltd, have our own stand at CPHI worldwide 2022 Frankfurt. Welcome to visit us from the 1st to the 3rd of November! Stand No.:121D70

Tirofiban is mainly used to treat acute coronary syndrome and prevent thrombosis after coronary arterial intervention.

We, Xi’an Wanlong Pharmaceutical Co., Ltd, has our own stand at CPHI worldwide 2022 Frankfurt. Welcome to visit us from the 1st to the 3rd of November!

Iron Dextran is an injectable low-molecular-weight ferric hydroxide complex indicated for patients with iron deficiency anemia where oral iron therapy is ineffective or poorly tolerated.

Tirofiban hydrochloride is the first non-polypeptide platelet membrane GP IIb/IIIa receptor antagonist.

Undoubtedly, increasing the ratio of pyruvate carboxylation can improve the utilization rate of carbon source, that is, can improve the yield of malic acid.

Compound Dextran 40 injection will become the preferred variety of blood volume expanders and will be brilliant in the field of plasma replacement!

The WHO ranked China's vaccine regulatory system at a functional level of maturity according to the WHO's global classification system for national medical product regulatory authorities.

In order to improve the company's environmental benefits, economic benefits and reduce pollutant emissions, in accordance with the notice of the Shaanxi Provincial Department of Ecology and Environmen

Tirofiban hydrochloride is a chemically synthesized non-peptide drug, which has two effects.

The difference in the physiological functions between D-malic acid and L-malic acid leads to their different uses in various aspects of social industry.

The consistency evaluation of L-Alanyl-L-glutamine Injection from Xi’an Wanlong Pharmaceutical was approved.

Compound Dextran 40 Injection used in hand and foot surgery can effectively expand the blood vessels of patients, improve blood circulation, and facilitate the recovery of hand and foot affected areas

Tirofiban hydrochloride is a reversible non-peptide platelet GP IIb/IIIa receptor antagonist, developed by Merck in the United States.

There are two aseptic processing for aseptic injections in pharmaceutical industry,terminal sterilization process and aseptic processing.